Universal Beteiligungs und Servicegesellschaft mbH Invests $2.15 Million in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Key Points

• Universal Beteiligungs und Servicegesellschaft mbH has acquired 65,585 shares in Supernus Pharmaceuticals, valued at approximately $2,148,000, representing about 0.12% ownership of the company.
• Other major investors have significantly increased their stakes, with Woodline Partners LP boosting its position by 124.8% and BNP Paribas Financial Markets by 248.0% during the last quarter.
• Analysts have mixed opinions on Supernus Pharmaceuticals, with Cantor Fitzgerald upgrading the stock to "overweight" with a price target of $42, while Wall Street Zen downgraded it from "buy" to "hold."

Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 65,585 shares of the specialty pharmaceutical company's stock, valued at approximately $2,148,000. Universal Beteiligungs und Servicegesellschaft mbH owned approximately 0.12% of Supernus Pharmaceuticals at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the company. Vident Advisory LLC boosted its holdings in shares of Supernus Pharmaceuticals by 2.2% in the 4th quarter. Vident Advisory LLC now owns 14,392 shares of the specialty pharmaceutical company's stock worth $520,000 after purchasing an additional 309 shares during the period. Summit Investment Advisors Inc. boosted its holdings in shares of Supernus Pharmaceuticals by 7.6% in the 4th quarter. Summit Investment Advisors Inc. now owns 5,253 shares of the specialty pharmaceutical company's stock worth $190,000 after purchasing an additional 369 shares during the period. Bank of Montreal Can boosted its holdings in shares of Supernus Pharmaceuticals by 6.6% in the 4th quarter. Bank of Montreal Can now owns 7,595 shares of the specialty pharmaceutical company's stock worth $275,000 after purchasing an additional 473 shares during the period. HighTower Advisors LLC boosted its holdings in shares of Supernus Pharmaceuticals by 7.3% in the 4th quarter. HighTower Advisors LLC now owns 9,130 shares of the specialty pharmaceutical company's stock worth $330,000 after purchasing an additional 624 shares during the period. Finally, Raiffeisen Bank International AG purchased a new position in shares of Supernus Pharmaceuticals in the 4th quarter worth approximately $25,000.

Wall Street Analyst Weigh In

SUPN has been the subject of a number of research analyst reports. Cantor Fitzgerald raised Supernus Pharmaceuticals from a "neutral" rating to an "overweight" rating and set a $42.00 price target for the company in a research note on Wednesday. Wall Street Zen lowered Supernus Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Sunday, July 20th.

Supernus Pharmaceuticals Trading Up 1.2%

Shares of SUPN traded up $0.41 during trading hours on Friday, hitting $35.51. The company had a trading volume of 858,699 shares, compared to its average volume of 590,504. The company has a market capitalization of $1.99 billion, a PE ratio of 31.99 and a beta of 0.70. Supernus Pharmaceuticals, Inc. has a one year low of $27.05 and a one year high of $40.28. The company's fifty day moving average price is $32.57 and its two-hundred day moving average price is $33.42.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.